Withdrawal of active treatment after intracerebral haemorrhage in the INTERACT2 study

Simple item page
dc.contributor.authorMuñoz Venturelli, Paula
dc.contributor.authorWang, Xia
dc.contributor.authorZahuranec, Darin B.
dc.contributor.authorLavados, Pablo
dc.contributor.authorStapf, Christian
dc.contributor.authorLindley, Richard
dc.contributor.authorDelcourt, Candice
dc.contributor.authorChalmers, John
dc.contributor.authorAnderson, Craig S.
dc.contributor.authorRobinson, Thompson G.
dc.contributor.authorTHOMPSON G. ROBINSON8, THOMPSON G. ROBINSON8 , FOR THE INTERACT2 INVESTIGATORS
dc.date.accessioned2022-03-10T20:14:46Z
dc.date.available2022-03-10T20:14:46Z
dc.date.issued2017
dc.description.abstractBackground: in the second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2), a minority of patients received withdrawal of active treatment (WAT). We wished to determine the characteristics of these patients, and the relation of this decision-making to subsequent management and final outcome. Methods: the INTERACT2 cohort of acute intracerebral haemorrhage (ICH) patients had a decision of WAT within 7 days after hospital admission recorded. Multivariable logistic regression was used to identify the determinants of WAT and poor outcome at 90 days, defined by modified Rankin scale (mRS) scores 3–6. Results: of 2,779 participants with available data, WAT occurred in 121 (4%) and this was significantly associated with increasing age, greater neurological severity, larger haematoma volume, intraventricular extension and randomisation to intensive BP lowering. Compared to other patients, those with WAT had greater mortality (81/121 [67%] versus 205/2624 [8%]; P < 0.001) and survivors were more likely to be severely disabled (mRS score 4–5, 19/39 [49%] versus 695/2419 [29%]; P = 0.006). Conclusions: WAT was undertaken in patients with recognised predictors of poor prognosis, who subsequently were more likely to die or be left with severe disability. Improved understanding of specific factors determining WAT in ICH patients might improve care delivery and outcomes. Clinical Trial Registration: the INTERACT2 study is registered with ClinicalTrials.gov (NCT00716079).es
dc.description.versionVersión Publicadaes
dc.identifier.citationMuñoz Venturelli P, Wang X, Zahuranec DB, Lavados PM, Stapf C, Lindley R, Delcourt C, Chalmers J, Anderson CS, Robinson TG, Robinson TG; INTERACT2 Investigators. Withdrawal of active treatment after intracerebral haemorrhage in the INTERACT2 study. Age Ageing. 2017 Mar 1;46(2):329-332. doi: 10.1093/ageing/afw187.es
dc.identifier.urihttps://doi.org/10.1093/ageing/afw187es
dc.identifier.urihttp://hdl.handle.net/11447/5694
dc.language.isoenes
dc.subjectIntracerebral haemorrhagees
dc.subjectWithdrawal of carees
dc.subjectWithdrawal of treatmentes
dc.subjectOutcomees
dc.subjectPrognosises
dc.subjectOlder peoplees
dc.titleWithdrawal of active treatment after intracerebral haemorrhage in the INTERACT2 studyes
dc.typeArticlees
dcterms.sourceAge Ageinges

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Withdrawal of active treatment after intracerebral haemorrhage in the INTERACT2 study.pdf
Size:
146.67 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services